Clinical Trial Update: CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273) [Phase 1, Phase 2]

View source ↗

Summary

The document reports a phase 1/2 clinical trial evaluating CD30-targeted CAR T cells for lymphomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• CD30-targeted CAR T cells (CD30-directed chimeric antigen receptor T cells)

Snippet

Sponsor: Peking University | Conditions: Lymphomas | Phase 1, Phase 2 | Status: UNKNOWN